Foghorn Therapeutics (FHTX) Enterprise Value (2020 - 2025)
Foghorn Therapeutics (FHTX) has 6 years of Enterprise Value data on record, last reported at -$1.2 million in Q4 2025.
- For Q4 2025, Enterprise Value rose 97.75% year-over-year to -$1.2 million; the TTM value through Sep 2025 reached -$90.6 million, down 57.05%, while the annual FY2025 figure was -$1.2 million, 97.75% up from the prior year.
- Enterprise Value reached -$1.2 million in Q4 2025 per FHTX's latest filing, up from -$90.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.2 million in Q4 2025 and bottomed at -$213.6 million in Q1 2022.
- Average Enterprise Value over 5 years is -$79.1 million, with a median of -$68.4 million recorded in 2021.
- Peak YoY movement for Enterprise Value: crashed 1829.97% in 2021, then soared 97.75% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$101.1 million in 2021, then skyrocketed by 48.37% to -$52.2 million in 2022, then plummeted by 53.86% to -$80.3 million in 2023, then surged by 30.97% to -$55.5 million in 2024, then skyrocketed by 97.75% to -$1.2 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$1.2 million in Q4 2025, -$90.6 million in Q3 2025, and -$73.8 million in Q2 2025.